Table 1.
Demographic and clinical characteristics separated by treatment arm.
| Study 1 (Adult) | CBT (N = 41) | SSRI (N = 40) | t Value | p Value |
|---|---|---|---|---|
| M (SD) | M (SD) | |||
| Age | 27.80 (8.98) | 25.70 (7.71) | 1.13 | 0.26 |
| T1 HAM-A symptoms | 16.15 (5.19) | 18.73 (6.93) | −1.85 | 0.08 |
| T2 HAM-A symptoms | 5.85 (4.58) | 7.13 (6.02) | −1.07 | 0.29 |
| TI HAM-D symptoms | 11.76 (3.66) | 12.83 (4.72) | −1.14 | 0.26 |
| T2 HAM-D symptoms | 4.68 (3.71) | 5.68 (4.56) | −1.08 | 0.29 |
| N (%) | N (%) | χ2 | ||
| Female | 29 (70.7%) | 29 (72.5%) | 0.03 | 0.53 |
| Caucasian | 27 (65.9%) | 25 (62.5%) | 0.10 | 0.47 |
| African American | 8 (19.5%) | 6 (15.0%) | 0.29 | 0.41 |
| Asian | 4 (9.8%) | 4 (10.0%) | 0.00 | 0.63 |
| American Indian | 0 (0.0%) | 1 (2.5%) | 1.04 | 0.49 |
| Biracial/other | 2 (4.9%) | 4 (10.0%) | 0.77 | 0.33 |
| Hispanic ethnicity | 7 (1%) | 9 (22.5%) | 0.38 | 0.37 |
| Study 2 (Youth) | CBT (N = 28) | SSRI (N = 27) | ||
| M (SD) | M (SD) | t Value | ||
| Age | 12.67 (3.75) | 14.81 (2.83) | −2.37 | 0.02 |
| T1 PARS symptoms | 23.46 (4.29) | 23.63 (4.67) | −0.14 | 0.89 |
| T2 PARS symptoms | 10.04 (6.83) | 10.59 (6.28) | −0.32 | 0.75 |
| T1 CDI symptoms | 11.82 (6.84) | 15.56 (8.01) | −1.86 | 0.08 |
| T2 CDI symptoms | 5.21 (5.45) | 6.30 (7.09) | −0.64 | 0.53 |
| N (%) | N (%) | χ2 | ||
| Female | 15 (53.5%) | 17 (62.9%) | 0.50 | 0.33 |
| Caucasian | 15 (53.5%) | 19 (70.3%) | 1.64 | 0.16 |
| African American | 2 (7.1%) | 1 (3.7%) | 0.32 | 0.51 |
| Asian | 0 (0.0%) | 2 (7.4%) | 2.15 | 0.24 |
| Native Hawaiian | 0 (0.0%) | 1 (3.7%) | 1.06 | 0.49 |
| Biracial/other | 11 (39.3%) | 4 (14.8%) | 4.15 | 0.07 |
| Hispanic ethnicity | 8 (28.6%) | 4 (14.8%) | 2.41 | 0.30 |
CBT cognitive-behavioral therapy, SSRI selective serotonin reuptake inhibitor, HAM-A Hamilton anxiety rating scale, HAM-D Hamilton depression rating scale, PARS pediatric anxiety rating scale, CDI children’s depression inventory, T1 pretreatment, T2 posttreatment